pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$BNTXBioNTech SE

$BNTX85.26-0.40%
Mainz, DEupdated 14h ago

BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes

🐶 often sniffed alongside

top 2
  • tagOncology3 co-mentions · 1 sources
  • tagBreast Cancer3 co-mentions · 1 sources
pipeline
7
marketed
0
phase 3
3
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(7)

pipeline depth7 products
Preclinical: 1Phase 2: 3Phase 3: 3
1Preclinical3Phase 23Phase 3
Phase 3
BNT-113
Recurrent Head And Neck Squamous Cell Carcinoma
Phase 3
pumitamig
Non-Small Cell Lung Cancer
Phase 3
trastuzumab pamirtecan
Endometrial Cancer
Phase 2
BNT-111
Metastatic Melanoma
Phase 2
DB-1311
Esophageal Squamous Cell Carcinoma (ESCC)
Phase 2
sacituzumab drozuntecan
Epithelial Ovarian Cancer
Preclinical
Urinary Tract Infections Program
Urinary Tract Infections

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 3, 2026
earnings
$BNTX85.26-0.40%
14d ago
BioNTech SE earnings
BioNTech SE
→
view all catalysts →

Active trials

  • phase2A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancerrecruitingn=380
  • phase3A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancerrecruitingn=480
  • phase3ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancerrecruitingn=558
  • phase2A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastomarecruitingn=75
  • phase3A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1active not recruitingn=358
  • phase1A First-in-human Clinical Trial to Test if the Investigational Drug BNT3219 is Safe and Potentially Beneficial for People With Advanced Solid Tumors When Given Alone or Together With Other Investigational Drugsnot yet recruitingn=207
  • phase1A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesionsactive not recruitingn=318
  • phase2A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)recruitingn=880
🐶 Hiring Signal
No open roles indexed yet — view BioNTech SE jobs →

News

no news has mentioned this company yet
identifiers
ticker
$BNTX
SEC CIK
0001776985
country
DE
source
sec_tickers
top tags
Oncology6NSCLC1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 12m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?